Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 13/20 | 0.58 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | USP2 | O75604 | 7/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27381029 | 0.92 | CYP2D6 (0.55) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL22526349 | 0.88 | CYP2D6 (0.67) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL27381145 | 0.87 | CYP2D6 (0.56) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL25603399 | 0.86 | CYP2D6 (0.54) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL27381021 | 0.85 | CYP2D6 (0.59) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL22794820 | 0.85 | PIK3CD (0.62) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL29088302 | 0.85 | TSHR (0.60) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL23518853 | 0.84 | CYP2D6 (0.44) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL22856411 | 0.84 | CYP2D6 (0.43) | CYP2D6TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL22849045 | 0.82 | CYP2D6 (0.41) | CYP2D6TSHRUSP2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CYP2D6 474/4885TSHR 3916/4885USP2 105/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CYP2D6 2910/4885TSHR 4388/4885USP2 1076/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CYP2D6 698/4885TSHR 1768/4885USP2 519/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CYP2D6 973/4885TSHR 3442/4885USP2 618/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885TSHR 3319/4885USP2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.